Siemens Seeks Approval to Bulk-Produce Controlled Drugs
Published Date: 4/28/2025
Notice
Summary
Siemens Healthcare Diagnostics, Inc. wants to get official approval to make large amounts of certain controlled substances. This means they’ll be able to produce these drugs legally and help supply medical needs. If approved, it could affect healthcare providers and patients by ensuring steady access to important medicines, with no immediate cost changes announced.
Analyzed Economic Effects
1 provisions identified: 1 benefits, 0 costs, 0 mixed.
Siemens Seeks Bulk Controlled‑Drug Approval
Siemens Healthcare Diagnostics, Inc. has applied to be registered as a bulk manufacturer of certain controlled substances. If approved, Siemens would be legally allowed to produce large amounts of those drugs and could help ensure steady access to important medicines for healthcare providers and patients. The notice states there are no immediate cost changes announced.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-11526, Implementation of the Substance Use-Disorder Prevention That Promotes Opioid Recovery and Treatment for Patients and Communities Act of 2018: Dispensing and Administering Controlled Substances for Medication-Assisted Treatment
Starting July 9, 2026, new rules make it easier for doctors and pharmacies to provide medicine that helps people recover from opioid addiction. These changes affect healthcare providers by expanding who can give medication-assisted treatment and how pharmacies can deliver these medicines. The goal? Faster, safer access to treatment with clear rules that save time and support recovery.
2026-10128, Revision of Applications for Manufacturing and Procurement Quotas
The DEA wants to update how companies apply for permission to make and buy certain controlled drugs and chemicals. These changes will make the rules clearer, help prevent drug shortages, and ensure enough supply for medical and scientific needs. If you’re a manufacturer or involved in this process, get ready to follow new steps and share your thoughts by July 20, 2026.
2025-05007, Expansion of Buprenorphine Treatment via Telemedicine Encounter and Continuity of Care via Telemedicine for Veterans Affairs Patients
Starting December 31, 2025, veterans can get buprenorphine treatment and follow-up care through telemedicine, making it easier to access help for opioid use disorder without leaving home. This change affects veterans using VA health services and aims to improve treatment access while the government reviews feedback and policies. No new costs are mentioned, but the delay gives agencies time to ensure the rules work well.
2025-02793, Expansion of Buprenorphine Treatment via Telemedicine Encounter and Continuity of Care via Telemedicine for Veterans Affairs Patients
The government is giving veterans easier access to buprenorphine treatment through telemedicine, letting them get care remotely. This change affects veterans using VA health services and aims to make treatment smoother and more convenient. The new rules were supposed to start February 18, 2025, but now they’ll kick in on March 21, 2025, while the government gathers public feedback.
2026-20749, Vladimir Romaniv, P.A.; Decision and Order
The DEA has officially suspended and is moving to revoke Vladimir Romaniv, P.A.'s registration because he gave multiple prescriptions without properly checking on a patient who was in jail. This affects Romaniv’s ability to prescribe controlled substances and signals serious legal trouble starting from late 2025. If you’re connected to his practice or rely on his prescriptions, expect changes and tighter controls soon.
2026-20750, L Krenk DBA Maui Clinic Pharmacy; Decision and Order
The DEA has officially revoked L Krenk DBA Maui Clinic Pharmacy’s registration because they broke important rules about where and how they handled controlled substances. This affects the pharmacy in Kahului, Hawaii, which can no longer legally dispense these drugs. The decision is final, and the pharmacy missed its chance to defend itself, so the revocation takes effect immediately, impacting their business and customers.
Previous / Next Documents
Previous: 2025-07281, Bulk Manufacturer of Controlled Substances Application: Pharmaron Manufacturing Services (US), LLC; Correction
The DEA fixed a mistake in their March 26, 2025 notice about Pharmaron Manufacturing Services (US), LLC’s application to make controlled substances in bulk. This update clears up what substances they plan to handle, so everyone’s on the same page. If you’re involved in drug manufacturing or regulation, this correction helps keep things accurate and fair—no money or timing changes, just clarity!
Next: 2025-07283, Importer of Controlled Substances Application: Lipomed
Lipomed wants to become an official importer of certain controlled substances, which means they’ll be bringing in specific drugs for medical or research use. This affects anyone tracking or regulating these substances and could impact supply chains soon. Keep an eye out for updates on approvals and any related deadlines or fees.